Baseline demographics and characteristics*
| Characteristics | TNFi-naïve (n=976) | TNFi-previous use (n=298) | TNFi-recent use (n=407) | All patients (n=1681) |
|---|---|---|---|---|
| Female, % (n) | 79 (773) | 84 (250) | 82 (333) | 81 (1356) |
| Age, years | 54 (12) | 53 (12) | 53 (12) | 54 (12) |
| Duration of RA, years | 8.2 (8.2) | 11.2 (8.6) | 11.7 (9.6) | 9.6 (8.8) |
| DAS28 | 5.9 (1.2) | 6.2 (1.2) | 6.0 (1.3) | 6.0 (1.2) |
| SJC | 12.1 (8.7) | 13.9 (9.6) | 13.4 (9.9) | 12.8 (9.2) |
| TJC | 21.9 (14.4) | 24.5 (15.8) | 23.8 (15.6) | 22.8 (15.0) |
| PtGA VAS | 60.7 (21.0) | 68.0 (21.4) | 62.9 (20.8) | 62.5 (21.2) |
| PhGA VAS | 57.3 (17.3) | 62.9 (17.5) | 59.5 (18.9) | 58.8 (17.9) |
| Pain VAS | 55.3 (22.3) | 63.1 (23.4) | 58.7 (22.0) | 57.5 (22.6) |
| CRP, mg/dl | 1.7 (2.5) | 2.4 (3.1) | 2.2 (3.1) | 1.9 (2.8) |
| ESR, mm/h | 37.6 (25.5) | 42.9 (28.9) | 40.5 (28.1) | 39.2 (26.8) |
| HAQ-DI | 1.4 (0.6) | 1.7 (0.6) | 1.6 (0.6) | 1.5 (0.6) |
| Previous DMARDs, n | 0.5 (0.9) | 2.5 (1.7) | 2.5 (1.6) | 1.3 (1.6) |
| Background DMARDs, % (n) | ||||
| 0 | 7 (66) | 21 (62) | 27 (111) | 14 (239) |
| 1 | 68 (659) | 71 (211) | 62 (254) | 67 (1124) |
| 2 | 22 (211) | 5 (16) | 8 (31) | 15 (258) |
| ≥3 | 4 (40) | 3 (9) | 3 (11) | 4 (60) |
| Patients receiving corticosteroids, % (n) | 47.0 (459) | 56.4 (168) | 48.2 (196) | 49.0 (823) |
| Mean corticosteroid dose,† mg/day | 6.83 | 7.85 | 7.57 | 7.22 |
| Leflunomide dose, mg/day | 18.2 (5.1) | 18.2 (4.5) | 19.0 (3.0) | 18.4 (4.6) |
| Methotrexate dose, mg/week | 17.4 (5.3) | 18.3 (12.9) | 17.0 (5.8) | 17.5 (7.3) |
| Sulfasalazine dose, g/day | 1.9 (0.6) | 1.7 (0.6) | 2.0 (0.6) | 1.9 (0.6) |
| Geographical distribution, % (n) | ||||
| Canada | 11.2 (109) | 10.4 (31) | 5.9 (24) | 9.8 (164) |
| Western Europe | 61.3 (598) | 81.5 (243) | 87.5 (356) | 71.2 (1197) |
| Other‡ | 27.6 (269) | 8.1 (24) | 6.6 (27) | 19.0 (320) |
↵* Data are presented as mean (SD), unless stated otherwise.
↵† Dose is expressed in prednisone equivalents for treated patients.
↵‡ Other includes Australia, Czech Republic, Greece, Hungary, India, Poland, Romania, Saudi Arabia and Turkey.
CRP, C-reactive protein; DAS28, disease activity score based on 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; IR, inadequate response; PtGA, patient global assessment; PhGA, physician global assessment; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor; TNFi-naive, patients who had never received TNFi therapy; TNFi-previous use, patients who had discontinued TNFi therapy for >2 months before baseline (washout period); TNFi-recent use, patients who had discontinued TNFi therapy for ≤2 months before baseline (no washout period); VAS, visual analogue scale.